3 recruiting, 3 terminated, 1 completed. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Terminated 3, Completed 1 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Recursion Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REC-7735 in Participants With Solid Tumors REC-7735 - Solid Tumors | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 90 | 2026-09-01 | 2026-09-29 |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| The Clostridioides Difficile Trial of REC-3964 REC-3964 - Recurrent Clostridioides Difficile Infection | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 3 | 2024-10-14 | 2025-11-17 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation REC-4881 - AXIN1 Gene Mutation, APC Gene Mutation | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 18 | 2024-01-15 | 2026-02-23 |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) REC-4881, Placebo - Familial Adenomatous Polyposis | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 67 | 2023-07-10 | 2026-06-05 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 REC-994, Placebo - Cerebral Cavernous Malformation | Phase 2 | Completed | Recursion Pharmaceuticals Inc. | 62 | 2022-03-17 | 2026-10-22 |
Neoplasms (2) · Adenomatous Polyposis Coli (1) · Clostridium Infections (1) · Hemangioma, Cavernous, Central Nervous System (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Neurofibromatosis 2 (1)
HDAC-42 (1)
United States (7) · Canada (1) · United Kingdom (1)